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The authors consider current and future prospects for primary hormone therapy in localized and 
locally advanced prostate cancer by comparing this form of treatment (hormone monotherapy) with 
町 oadjuvantradiation therapy and radical prostatectomy. Neoadjuvant hormone therapy prior to 
radiation therapy has been proven effective in recent years， and currently the United States is showing a 
year-by-year increase in the use ofandrogen blocking agents during the early stage ofprostate cancer. 
A survey of recent research findings， clearly showed that， for patients with localized prostate 
cancer， there is no significant difference in survival rate between hormone monotherapy and radical 
prostatectomy. In the future we can expect to see an increase in available treatment options for 
localized and locally advanced prostate cancer， with the optimal therapy for each individual patient to 
be selected by the attending physician in discussion with the patient. 
(Acta Urol. Jpn. 49: 771-777， 2003) 
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cal margins， PSM)，リンパ節転移陽性の頻度は
NAT群に有意に少なかった.術前の前立腺特異抗原




























は B2とCの患者群で NATによる有意な down-
staging効果(それぞれp=0.0102，p=0.0066)が認
められた (Table1).局所進行のみられなかった臓器




































Table 1. Clinical stage and pathological stage 
pTO pNTO 2a pNTO 2b 込3 pN+ NE 
Neo+ 5 2 
A2 
Neo一 2 5 3 
有意差なし
Neo+ 5 2 3 10 3 
B1 
Neo一 2 4 12 
有意差なし
Neo十 3 ¥0 18 4 
B2 
Neo一 4 16 p=0.0102 ¥0 
Neo+ 2 13 5 
C 
Neo一 9 p=0.0066 14 
Neo+ 13 7 14 43 12 
Neo一 2 8 1 38 26 
p=0.0051 
Neo+ :ネオアジュパントあり， Neo-・ネオアジュパントなし， NO 区域リンパ節転移なし， NE:評価不能.
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初回治療後の経過(年)
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独群とを比較した研究 (RTOG85“31)6) や. Gran-
forsらの研究 (UMEAtriaO 7)などがある.
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2 4 6 8 10 12 
アンドロゲン遮断療法継続期間(年)
Effect of duration of continuous CAB on the % of pa-
tients with PSA remaining under control for a mini-







































(pi1epich et aI. 1997) lーの前立腺癌治趨倒11)(Labrie F eta1.2∞2) 
4 
1940 1950 1960 1970 1980 1990 2000 (年)
CAB併用アンドロゲン遮断療法， NAT:ネオアジュパント療法






























































的癌組織比率 (visualestimate of percentage of carci-
























2003年の AUAで発表された CaFSURE(Cancer 












































of hormone demerits Merits and 
therapy 
Table 2. 
20%) ，高度 (>20%)の3群に分け， 12カ月以上追
跡した結果，各群の PSA非再燃患者比率はそれぞれ
94%， 82%， 67%で，多変量解析の結果， PSA再燃
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